化疗内分泌治疗与内分泌治疗对乳腺癌患者认知障碍的影响:RxPONDER随机临床试验二次分析
该研究为RxPONDER试验的预设二次分析,纳入568例激素受体阳性、ERBB2阴性、1-3枚淋巴结阳性且Oncotype DX复发评分≤25的乳腺癌患者,随机接受化疗+内分泌治疗(CET)或单纯内分泌治疗(ET)。结果显示,在36个月随访中,CET与患者报告的癌症相关认知障碍(CRCI)负相关程度均大于ET,且绝经前和绝经后患者均如此。
要点
- CET较ET在绝经前和绝经后患者中均与更差的患者报告认知功能相关。
- 绝经前患者ET组PCF评分在36个月恢复至基线,而CET组未恢复。
- 绝经后患者ET组PCF评分基本稳定,CET组在6和12个月下降且36个月未恢复。
核心结论
- 在36个月随访中,CET较单纯ET与患者报告的CRCI负相关程度更大,且绝经前和绝经后患者均如此。
研究设计与样本
- RxPONDER(SWOG S1007)为多国3期随机临床试验,纳入超过5000例激素受体阳性、ERBB2阴性、1-3枚淋巴结阳性且Oncotype DX复发评分≤25的乳腺癌患者。
- 本分析为预设二次分析,纳入568例完成基线问卷的患者,随机分配至CET或ET,采用PROMIS PCF问卷在基线、6、12和36个月评估认知功能。
主要发现
- 绝经前患者ET组PCF评分从基线至6和12个月下降(53.53、51.51、51.72),36个月恢复至基线(54.36)。
- 绝经后患者ET组PCF评分基本稳定(51.72、51.13、51.11、51.70)。
- CET组绝经前患者PCF评分从基线至6和12个月下降(52.84、49.27、48.04),36个月未恢复至基线(49.25)。
- CET组绝经后患者PCF评分从基线至6和12个月下降(50.65、48.39、47.13),36个月未恢复至基线(48.44)。
临床怎么用
- 对于接受CET的乳腺癌患者,尤其是绝经前和绝经后患者,应关注认知功能变化并考虑干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the association of endocrine therapy (ET) vs chemotherapy plus endocrine therapy (CET) with CRCI is poorly understood. OBJECTIVE: To compare patient-reported CRCI between women with breast cancer treated with ET vs CET and to consider whether menopausal status may be associated. DESIGN, SETTINGS, AND PARTICIPANTS: This was a prespecified secondary analysis of RxPONDER (SWOG S1007), a multinational phase 3 randomized clinical trial of more than 5000 women with hormone receptor-positive ERBB2-negative (formerly HER2-negative) breast cancer with 1 to 3 involved lymph nodes and Oncotype DX (21-gene recurrence score) of 25 or less. Participants were enrolled from February 2011 to September 2017, with results first reported in December 2020. Participants were randomly assigned to CET or ET, with ongoing follow-up. This secondary analysis assessed cognitive function using the Patient-Reported Outcomes Measurement Information System Perceived Cognitive Function Concerns (PCF) questionnaire at baseline, 6, 12, and 36 months. Data were analyzed from July 2022 to August 2025. INTERVENTION: Random assignment to CET or ET. MAIN OUTCOMES AND MEASURES: Mean PCF standardized (T) scores by menopausal status over time using generalized estimating equations analysis for continuous outcomes. RESULTS: Of the 568 patients who completed the baseline questionnaire and were included in the analysis, 139 (24%) were premenopausal (median [range] age, 47.8 [28.0-56.3] years) and 429 (76%) were postmenopausal (median [range] age, 62.3 [37.3-87.6] years). Among the 274 (48%) who received CET and the 294 (52%) who received ET alone, CET was determined to have a greater negative association with patient-reported CRCI in both the pre- and postmenopausal participants during the 36-month follow-up. In the ET alone group, PCF scores for premenopausal participants decreased from baseline to 6 and 12 months (53.53, 51.51, and 51.72, respectively) but recovered to baseline (54.36) at 36 months. For postmenopausal participants, mean PCF scores were essentially stable (51.72, 51.13, 51.11, and 51.70, respectively); however, in the CET group, PCF scores for both pre- and postmenopausal participants decreased from baseline to 6 and 12 months (premenopausal, 52.84, 49.27, 48.04; postmenopausal, 50.65, 48.39, 47.13, respectively) and did not return to baseline at 36 months (premenopausal, 49.25; postmenopausal, 48.44). The difference in longitudinal mean PCF scores over time between CET and ET groups was -3.02 (95% CI, -5.33 to -0.72; P = .01) for premenopausal and -2.37 (95% CI, -3.92 to -0.82; P = .003) for postmenopausal participants. CONCLUSIONS AND RELEVANCE: This secondary analysis of the RxPONDER found that CET had a greater negative association with patient-reported CRCI compared to ET alone in both pre- and postmenopausal participants over a 36-month follow-up period. Interventions to prevent or treat CRCI are needed to improve the long-term quality of life of these patients treated with chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01272037.
引用
- Kang IM, Forschmiedt JK, Loch MM, et al. Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41379459. doi:10.1001/jamaoncol.2025.5220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。